Banca Mediolanum Valuation
Is BMEDM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BMEDM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BMEDM (€11.63) is trading below our estimate of fair value (€12.14)
Significantly Below Fair Value: BMEDM is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BMEDM?
Key metric: As BMEDM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BMEDM's PE Ratio? | |
|---|---|
| PE Ratio | 8.8x |
| Earnings | €924.04m |
| Market Cap | €8.16b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | -2.3x |
Price to Earnings Ratio vs Peers
How does BMEDM's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.5x | ||
MNG M&G | 28.2x | 28.5% | UK£4.7b |
WISE Wise | 20.8x | -6.5% | UK£9.0b |
HL. Hargreaves Lansdown | 17.6x | 1.6% | UK£5.2b |
ICG Intermediate Capital Group | 15.5x | 11.7% | UK£6.2b |
BMEDM Banca Mediolanum | 8.8x | -3.9% | €8.2b |
Price-To-Earnings vs Peers: BMEDM is good value based on its Price-To-Earnings Ratio (8.8x) compared to the peer average (20.5x).
Price to Earnings Ratio vs Industry
How does BMEDM's PE Ratio compare vs other companies in the GB Diversified Financial Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
NBS Nationwide Building Society | 0.9x | n/a | US$1.51b |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: BMEDM is good value based on its Price-To-Earnings Ratio (8.8x) compared to the UK Diversified Financial industry average (13.3x).
Price to Earnings Ratio vs Fair Ratio
What is BMEDM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BMEDM's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €12.85 0% | 3.5% | €13.50 | €12.00 | n/a | 12 |
| Nov ’25 | €11.40 | €12.65 +11.0% | 4.4% | €13.50 | €11.70 | n/a | 12 |
| Oct ’25 | €11.20 | €12.53 +11.9% | 4.1% | €13.50 | €11.70 | n/a | 12 |
| Sep ’25 | n/a | €12.53 0% | 4.1% | €13.50 | €11.70 | n/a | 12 |
| Aug ’25 | n/a | €12.23 0% | 5.1% | €13.50 | €10.90 | n/a | 12 |
| Jul ’25 | €10.59 | €12.15 +14.7% | 4.6% | €13.00 | €10.90 | n/a | 12 |
| Jun ’25 | €10.52 | €12.12 +15.2% | 4.7% | €13.00 | €10.90 | n/a | 12 |
| May ’25 | n/a | €11.55 0% | 5.5% | €12.80 | €10.80 | n/a | 12 |
| Apr ’25 | n/a | €11.38 0% | 3.9% | €12.00 | €10.80 | n/a | 12 |
| Mar ’25 | n/a | €11.29 0% | 3.6% | €12.00 | €10.80 | n/a | 12 |
| Feb ’25 | n/a | €10.88 0% | 5.8% | €11.80 | €9.50 | n/a | 12 |
| Jan ’25 | n/a | €10.58 0% | 6.3% | €11.50 | €9.20 | n/a | 12 |
| Dec ’24 | n/a | €10.60 0% | 6.0% | €11.50 | €9.20 | n/a | 12 |
| Nov ’24 | n/a | €10.60 0% | 6.0% | €11.50 | €9.20 | €11.40 | 12 |
| Oct ’24 | €8.17 | €10.69 +30.9% | 5.4% | €11.50 | €9.70 | €11.20 | 12 |
| Sep ’24 | n/a | €10.68 0% | 5.4% | €11.50 | €9.70 | n/a | 12 |
| Aug ’24 | n/a | €10.71 0% | 5.4% | €11.50 | €9.70 | n/a | 12 |
| Jul ’24 | n/a | €10.71 0% | 4.4% | €11.40 | €9.80 | €10.59 | 12 |
| Jun ’24 | n/a | €10.78 0% | 5.0% | €11.70 | €9.80 | €10.52 | 12 |
| May ’24 | n/a | €10.92 0% | 4.3% | €11.70 | €10.00 | n/a | 12 |
| Apr ’24 | n/a | €10.96 0% | 4.5% | €11.70 | €10.00 | n/a | 12 |
| Mar ’24 | €9.20 | €10.96 +19.1% | 4.5% | €11.70 | €10.00 | n/a | 12 |
| Feb ’24 | n/a | €9.80 0% | 4.7% | €10.60 | €9.10 | n/a | 11 |
| Jan ’24 | €7.82 | €9.72 +24.3% | 4.4% | €10.50 | €9.10 | n/a | 11 |
| Dec ’23 | €7.87 | €9.58 +21.8% | 6.2% | €10.50 | €8.60 | n/a | 11 |
| Nov ’23 | n/a | €9.17 0% | 4.2% | €9.70 | €8.60 | n/a | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
ASA International Group
UK£64.8m
Provides microfinancing services in Africa and Asia.
ASAI
UK£0.65
7D
1.6%
1Y
48.5%
HAL Trust
€10.4b
Operates through multi-sectors in Europe, the United States, Canada, Asia, and internationally.
0K9V
€115.80
7D
1.6%
1Y
1.6%
Man Group
UK£2.4b
Man Group Limited is a publicly owned investment manager.
EMGL
UK£2.11
7D
0.1%
1Y
-2.5%